Our data highlight the metabolic changes upon palbociclib treatment in A549 cells and may support the of targeting CDK4/6 inhibition in combination with glutaminase inhibitors in NSCLC patients with RB-proficient tumors. This evidence concerns the gene GLS and non-small cell lung carcinoma.